According to a newly published market research report by 24LifeSciences, the global Ad5-nCoV vaccine market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.5% during the forecast period 2025-2032.
Ad5-nCoV, developed by CanSino Biologics, is a recombinant adenovirus type-5 vectored COVID-19 vaccine...
According to a newly published market research report by 24LifeSciences, the global Ad5-nCoV vaccine market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.5% during the forecast period 2025-2032.
Ad5-nCoV, developed by CanSino Biologics, is a recombinant adenovirus type-5 vectored COVID-19 vaccine...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt